These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3552712)

  • 41. Intraerythrocytic administration of a synthetic Plasmodium antigen elicits antibody response in mice, without carrier molecules or adjuvants.
    Esposito F; Santroni AM; Habluetzel A; Grelloni V; Pessi A; Lombardi S; Falcioni G; Brunori M
    Int J Parasitol; 1990 Dec; 20(8):1109-11. PubMed ID: 2074141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.
    Haddad D; Liljeqvist S; Ståhl S; Hansson M; Perlmann P; Ahlborg N; Berzins K
    Scand J Immunol; 1999 May; 49(5):506-14. PubMed ID: 10320644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The humoral immune responses elicited in mice by inoculations with a recombinant protein or DNA based on the circumsporozoite-protein gene of Plasmodium falciparum.
    Fang Z; Liu YW; Shi YK; Yu XB; Huang WQ; Ji X
    Ann Trop Med Parasitol; 2002 Jul; 96(5):463-8. PubMed ID: 12194706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.
    Alving CR; Richards RL; Moss J; Alving LI; Clements JD; Shiba T; Kotani S; Wirtz RA; Hockmeyer WT
    Vaccine; 1986 Sep; 4(3):166-72. PubMed ID: 3532603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of Plasmodium falciparum antigenic determinants produced by Escherichia coli recombinant clones.
    Mercereau-Puijalon O; Blisnick T; Fandeur T; Dedet JP; Roussilhon C; Guillotte M; Kahane B; Breton C; Siffert O; Griesser HW
    Ann Inst Pasteur Immunol; 1986; 137D(1):63-78. PubMed ID: 2428279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2.
    Saul A; Lord R; Jones GL; Spencer L
    J Immunol; 1992 Jan; 148(1):208-11. PubMed ID: 1727867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Age-specific prevalence of antibody to a synthetic peptide of the circumsporozoite protein of Plasmodium falciparum in children from three villages in Kenya.
    Campbell GH; Collins FH; Brandling-Bennett AD; Schwartz IK; Roberts JM
    Am J Trop Med Hyg; 1987 Sep; 37(2):220-4. PubMed ID: 3310677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.
    Lupski JR
    N Engl J Med; 1987 Feb; 316(7):415. PubMed ID: 3100954
    [No Abstract]   [Full Text] [Related]  

  • 50. Genetic restriction of the murine humoral response to a recombinant Plasmodium vivax circumsporozoite protein.
    Nardin EH; Barr PJ; Heimer E; Etlinger HM
    Eur J Immunol; 1988 Jul; 18(7):1119-22. PubMed ID: 3136025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide.
    Kumar A; Arora R; Kaur P; Chauhan VS; Sharma P
    J Immunol; 1992 Mar; 148(5):1499-505. PubMed ID: 1371529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of a sporozoite antigen common to Plasmodium falciparum and Plasmodium berghei.
    Sina BJ; Wright C; Atkinson CT; Ballou R; Aikawa M; Hollingdale M
    Mol Biochem Parasitol; 1995 Feb; 69(2):239-46. PubMed ID: 7770087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune responses to the circumsporozoite protein of Plasmodium falciparum in relation to HLA-DR type.
    Brown AE; Chandanayingyong D; Fuggle SV; Webster HK
    Tissue Antigens; 1989 Sep; 34(3):200-4. PubMed ID: 2688192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines.
    Del Giudice G; Cooper JA; Merino J; Verdini AS; Pessi A; Togna AR; Engers HD; Corradin G; Lambert PH
    J Immunol; 1986 Nov; 137(9):2952-5. PubMed ID: 3531341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of Malaysian sera with Plasmodium vivax sporozoite antigen.
    Lee M; Davis DR; Ballou WR; Folena-Wasserman G; Lewis GE
    Am J Trop Med Hyg; 1988 Dec; 39(6):535-9. PubMed ID: 3061309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.
    Hui GS; Gosnell WL; Case SE; Hashiro C; Nikaido C; Hashimoto A; Kaslow DC
    J Immunol; 1994 Sep; 153(6):2544-53. PubMed ID: 8077664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
    Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.